This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pohl, G. Articles by Shih, I.-M. Search for Related Content PubMed PubMed Citation Articles by Pohl, G. Articles by Shih, I.-M.

Inactivation of the Mitogen-Activated Protein Kinase Pathway as a Potential Target-Based Therapy in Ovarian Serous Tumors with KRAS or BRAF Mutations

Departments of ¹ Pathology and ² Oncology and Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland

Requests for reprints: Ie-Ming Shih, Johns Hopkins Medical Institutions, 1503 East Jefferson Street, Room B-315, Baltimore, MD 21231. Phone: 410-502-7774; Fax: 410-502-7943; E-mail: ishih{at}jhmi.edu.

Activation of mitogen-activated protein kinase (MAPK) occurs in response to various growth stimulating signals and as a result of activating mutations of the upstream regulators, KRAS and BRAF, which can be found in many types of human cancer. To investigate the roles of MAPK activation in tumors harboring KRAS or BRAF mutations, we inactivated MAPK in ovarian tumor cells using CI-1040, a compound that selectively inhibits MAPK kinase, an upstream regulator of MAPK and thus prevents MAPK activation. Profound growth inhibition and apoptosis were observed in CI-1040-treated tumor cells with mutations in either KRAS or BRAF in comparison with the ovarian cancer cells containing wild-type sequences. Long serial analysis of gene expression identified several differentially expressed genes in CI-1040-treated MPSC1 cells harboring an activating mutation in BRAF (V599L). The most striking changes were down-regulation of cyclin D1, COBRA1, and transglutaminase-2 and up-regulation of tumor necrosis factor–related apoptosis-induced ligand, thrombospondin-1, optineurin, and palladin. These patterns of gene expression were validated in other CI-1040-treated tumor cells based on quantitative PCR. Constitutive expression of cyclin D1 partially reversed the growth inhibitory effect of CI-1040 in MPSC1 cells. Our findings indicate that an activated MAPK pathway is critical in tumor growth and survival of ovarian tumors with KRAS or BRAF mutations and suggest that the CI-1040 induced phenotypes depend on the mutational status of KRAS and BRAF in ovarian tumors.

Key Words: KRAS • BRAF • CI-1040 • ovarian cancer • MAP kinase

This article has been cited by other articles:

				L. Quaye, S. A. Gayther, S. J. Ramus, R. A. Di Cioccio, V. McGuire, E. Hogdall, C. Hogdall, J. Blaakr, D. F. Easton, B. A.J. Ponder, et al. The Effects of Common Genetic Variants in Oncogenes on Ovarian Cancer Survival Clin. Cancer Res., September 15, 2008; 14(18): 5833 - 5839. [Abstract] [Full Text] [PDF]

				J. J.-C. Sheu, J. H. Choi, I. Yildiz, F.-J. Tsai, Y. Shaul, T.-L. Wang, and I.-M. Shih The Roles of Human Sucrose Nonfermenting Protein 2 Homologue in the Tumor-Promoting Functions of Rsf-1 Cancer Res., June 1, 2008; 68(11): 4050 - 4057. [Abstract] [Full Text] [PDF]

				M. Xing BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications Endocr. Rev., December 1, 2007; 28(7): 742 - 762. [Abstract] [Full Text] [PDF]

				D. Liu, Z. Liu, D. Jiang, A. P. Dackiw, and M. Xing Inhibitory Effects of the Mitogen-Activated Protein Kinase Kinase Inhibitor CI-1040 on the Proliferation and Tumor Growth of Thyroid Cancer Cells with BRAF or RAS Mutations J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4686 - 4695. [Abstract] [Full Text] [PDF]

				C. Spittle, M. R. Ward, K. L. Nathanson, P. A. Gimotty, E. Rappaport, M. S. Brose, A. Medina, R. Letrero, M. Herlyn, and R. H. Edwards Application of a BRAF Pyrosequencing Assay for Mutation Detection and Copy Number Analysis in Malignant Melanoma J. Mol. Diagn., September 1, 2007; 9(4): 464 - 471. [Abstract] [Full Text] [PDF]

				T. C. Yeh, V. Marsh, B. A. Bernat, J. Ballard, H. Colwell, R. J. Evans, J. Parry, D. Smith, B. J. Brandhuber, S. Gross, et al. Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor Clin. Cancer Res., March 1, 2007; 13(5): 1576 - 1583. [Abstract] [Full Text] [PDF]

				I.-M. Shih and R. J. Kurman Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges Clin. Cancer Res., October 15, 2005; 11(20): 7273 - 7279. [Abstract] [Full Text] [PDF]

				N. L.G. Sieben, J. Oosting, A. M. Flanagan, J. Prat, G. M.J.M. Roemen, S. M. Kolkman-Uljee, R. van Eijk, C. J. Cornelisse, G. J. Fleuren, and M. van Engeland Differential Gene Expression in Ovarian Tumors Reveals Dusp 4 and Serpina 5 As Key Regulators for Benign Behavior of Serous Borderline Tumors J. Clin. Oncol., October 10, 2005; 23(29): 7257 - 7264. [Abstract] [Full Text] [PDF]

				M. Kobel, G. Pohl, W. D. Schmitt, S. Hauptmann, T.-L. Wang, and I.-M. Shih Activation of Mitogen-Activated Protein Kinase Is Required for Migration and Invasion of Placental Site Trophoblastic Tumor Am. J. Pathol., September 1, 2005; 167(3): 879 - 885. [Abstract] [Full Text] [PDF]